Date: 2012-08-22
Type of information: Development agreement
Compound: miR-7 mimetic
Company: Silence Therapeutics (UK) MiReven Pty (Australia)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
development
Action mechanism:
Disease: various cancers known to be controlled by the EGF receptor signaling pathway
Details: Silence Therapeutics, a RNA interference (RNAi) therapeutics company, has signed an agreement with MiReven Pty Ltd, to assess the delivery potential of Silence’s proprietary delivery systems with MiReven’s novel microRNA-based therapeutics. MiReven, an Australian-based microRNA company, is commercialising discoveries from the Western Australian Institute for Medical Research (WAIMR) on the anti-cancer potential of miR-7. miR-7 has the potential to suppress tumour growth, particularly in the many cancers known to be controlled by the EGF receptor signaling pathway including glioblastoma.
Under the terms of the agreement, Silence will formulate a miR-7 mimetic (a potentially therapeutic mimic of the miR-7 molecule) with its proprietary AtuPLEX™, DACC and DBTC delivery systems in order to evaluate miR-7 in various cancer models. Silence will undertake in vitro and in vivo studies of the formulated miR-7. Silence is being paid an undisclosed fee for the collaboration.
AtuPLEX™, has demonstrated broad systemic delivery to the vascular endothelium. The AtuPLEX™ delivery system is used in Atu027, Silence’s lead oncology candidate in Phase I trials.
DACC, closely related to AtuPLEX™, is a novel lipid delivery system that enables functional, highly specific and efficient delivery of RNAi therapeutics to the pulmonary vascular endothelium.
DBTC is a novel lipid-based formulation that functionally delivers siRNA to liver endothelial cells, hepatocytes and other liver cell types with high efficiency.
Financial terms:
Latest news:
